Glycomimetics Stock Last Dividend Paid
| GLYC Stock | USD 0.35 0.04 12.90% |
GlycoMimetics fundamentals help investors to digest information that contributes to GlycoMimetics' financial success or failures. It also enables traders to predict the movement of GlycoMimetics Stock. The fundamental analysis module provides a way to measure GlycoMimetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlycoMimetics stock.
GlycoMimetics | Last Dividend Paid |
GlycoMimetics Company Last Dividend Paid Analysis
GlycoMimetics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
GlycoMimetics Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for GlycoMimetics is extremely important. It helps to project a fair market value of GlycoMimetics Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since GlycoMimetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlycoMimetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlycoMimetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, GlycoMimetics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
GlycoMimetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of GlycoMimetics from analyzing GlycoMimetics' financial statements. These drivers represent accounts that assess GlycoMimetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlycoMimetics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 228.8M | 171.9M | 74.1M | 159.2M | 149.5M | 127.3M | |
| Enterprise Value | 74.2M | 37.7M | (14.2M) | 112.2M | 108.5M | 66.5M |
GlycoMimetics Fundamentals
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 6.06 M | ||||
| Shares Outstanding | 64.48 M | ||||
| Shares Owned By Insiders | 3.12 % | ||||
| Shares Owned By Institutions | 47.91 % | ||||
| Number Of Shares Shorted | 3.8 M | ||||
| Price To Earning | (7.99) X | ||||
| Price To Book | 1.77 X | ||||
| Price To Sales | 2,237 X | ||||
| Revenue | 10 K | ||||
| Gross Profit | 75 K | ||||
| EBITDA | (39.12 M) | ||||
| Net Income | (36.9 M) | ||||
| Cash And Equivalents | 60.24 M | ||||
| Cash Per Share | 1.15 X | ||||
| Total Debt | 808.4 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 6.85 X | ||||
| Book Value Per Share | 0.60 X | ||||
| Cash Flow From Operations | (34.88 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (0.62) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 22.37 M | ||||
| Total Asset | 45.32 M | ||||
| Retained Earnings | (456.49 M) | ||||
| Working Capital | 36.96 M | ||||
| Current Asset | 46.52 M | ||||
| Current Liabilities | 5.42 M | ||||
| Net Asset | 45.32 M |
About GlycoMimetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlycoMimetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlycoMimetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlycoMimetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:Check out GlycoMimetics Piotroski F Score and GlycoMimetics Altman Z Score analysis. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Quarterly Revenue Growth (1.00) | Return On Assets (0.59) | Return On Equity (1.04) |
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.